WAUKESHA, WI (June 30, 2006) – Prodesse, Inc. announced today that effective July 1, 2006 the company has entered into an IVD Patents License Agreement with Roche. Prodesse is now granted the right to manufacture real time products which laboratories can use to develop and validate assays for the detection of certain diagnostic targets with the additional authority to convey rights to the service provider. Commenting on the agreement, Prodesse CEO Tom Shannon remarked, “We are quite pleased that Prodesse is now able to include Roche enzymes in its products as well as convey end-user rights under their patents to its customers with sale of Prodesse products for influenza a virus, Influenza B virus, RSV and human metapneumovirus.”
